Efficient risk mitigation planning for a clinical trial

Vladimir Shnaydman, Ph.D., ORBee Consulting, President
57 East Bluff Rd. Ashland MA 01721
vladimir.shnaydman@orbeeconsulting.com

Keywords: Risk planning, contingency budget, risk tolerance, optimization, risk mitigation, strategy, mitigation cost, probability of occurrence, impact, risk score.

Abstract
Each clinical trial faces numerous risks. Neglecting or reacting spontaneously at each materialized risk may delay trial completion, affect trial objectives and even derail the clinical trial. At the same time, pre-allocating excessive contingency resources to eliminate all potential risks, even with a low probability of occurrence and impact, may not be necessary. Therefore, optimal risk planning means finding the "right" balance between contingency resources, risk mitigation strategy, and risk tolerance.

Most risk planning publications focus only on risk identification and risk assessment. Risk mitigation strategy planning is often overlooked. Therefore, to derive an effective clinical trial risk mitigation strategy, a new methodology based on mathematical modeling was developed and validated for a Ph2 clinical trial.

Introduction

Clinical trials are complex projects with numerous risks that could influence their outcome. Risks could be associated with potentially low enrolling sites, protocol amendments, adverse events, high dropout rate, clinical supply stock-out, biological sample handling, etc. Poor risk planning can potentially delay or even compromise clinical trial results. Therefore, risk planning should be integral to risk-based quality management (RBQM) and clinical trial budgeting. If a risk event occurs during clinical trial execution without proper pre-allocated contingency resources, trial execution could be significantly delayed or even compromised.

The typical risk planning process includes several interconnected steps: identification of potential risks, risk assessment, risk response plan development, and risk monitoring.

Risks identification. Potential project risks could be identified via interviewing, risk registers of previous projects, etc.

Risks assessment. Qualitative risk analysis will be used to evaluate potential risks in clinical trials due to the broad diversity of risks and the absence of relevant data for quantitative risk analysis[1]. Qualitative risk analysis includes subjective judgment of the risk as the probability of an unfortunate event and impact, typically on some numerical scale, e.g., from 1 to 5. The risk score is a product of the risk probability (or risk) and its impact. The technique is described in many sources, for example, in [1,2].

The risk response plan aims to reduce risk and its impact. Several options could be considered: risk avoidance (an alternative approach that does not include a particular risk), risk prevention, risk acceptance, and risk mitigation.

In this paper, risk mitigation assumes that several mutually exclusive mitigation actions could be associated with each risk. For example, backup clinical sites could be selected in countries A or B.

Although there is a consensus that developing risk mitigation plans is an integral part of clinical trial risk management, only a few mainly descriptive papers on the subject were published in the last few years [3-7]. The author could not find commonly accepted techniques, models, or analytical tools to support the derivation of effective risk mitigation strategies for a clinical trial. Most efforts in risk analytics focus on risk identification, assessment, and monitoring. A contingency budget is routinely assigned as a percentage of a clinical trial budget, e.g., 10-20%. It is not aligned with the clinical trial risk level.

At the same, the risk mitigation planning problem was addressed in many papers applied to other industries, e.g., construction. The authors [8-17] developed sophisticated analytical tools ranging from optimization to Monte Carlo simulation.

Optimization tools [8-12, 14] are used for budget/contingency budget allocation. Monte Carlo simulation tools are applied for risk mitigation analysis for project and portfolio planning, where critical risk metrics like project delay, cost of the delay, and lost revenue can be used. Calculating the risk impact in terms of costs,

---

[1] Quantitative risk analysis can be used only if data is available to measure and predict a risk event's probability and impact (e.g., project delay, loss of revenue, etc.). It typically involves numerical analyses of the effects of risks, such as time and cost.

time delay, and lost revenue is rewarding. However, deriving these parameters in clinical trials is challenging because product risks (e.g., risk of insufficient adverse events reporting or under-enrollment) with uncertain impact on the clinical trial performance dominate the clinical trial risk landscape.

The modeling approach presented in the paper was developed to address the following questions.

a) How to align the contingency budget and product risk[2]?
b) How to allocate a contingency budget optimally across risks, risk categories, and business groups responsible for risk mitigation?
c) How to optimize the risk mitigation strategy for a clinical trial and select an optimal set of mitigation options to reduce clinical trial risk to a certain level of manageability?
d) How to align a contingency budget, mitigation strategy, clinical trial risk capacity, appetite, and tolerance[3]?

The clinical trial risk mitigation complexity (e.g., multiple risks, many mitigation options per risk, risk mitigation effect uncertainty) requires the implementation of the mathematical modeling technique based on a set of interconnected optimization (Risk Optimizer) and simulation (Risk Simulator) models. The Risk Optimizer optimizes the risk mitigation plan and pre-allocates resources, answering questions (a)-(c). The Risk Simulator mimics contingency plan execution and provides recommendations for aligning contingency budget, risk capacity, appetite, and tolerance answering question (d).

The paper organizes as follows. The first part describes the modeling methodology and its elements. The second part presents the application of the technique to a case study related to a Ph2 clinical trial, including data collection, modeling experiments, and analysis of the results. The paper will conclude with remarks regarding future research.

Part 1. Modeling methodology

Risk Optimizer

Elements of the model

---

[2] For simplicity, the term "risk" will be used in the paper instead of "product risk."
[3] In the paper, risk tolerance is defined as the probability that a selected mitigation strategy will be accomplished.

1. Risk identification and assessment

This paper assumes that each clinical trial risk **i** is characterized by two parameters – impact (S_i) and probability of occurrence (L_i) in a range (e.g., from 1 to 5). The product of these components is a risk score M_i.

$$M_i = S_i \times L_i \qquad (1)$$

The risk score is an indicator of risk priority. The higher the risk score, the more attention should be paid to this risk.

The risk impact and the probability of occurrence are subjective parameters and scaled from 1 to 5 (Tables 1 and 2).

Probability - L	1	2	3	4	5
Rating	Very low	Low	Medium	High	Very high
Average, %, P	10	25	50	75	90
Range, %	5-15	15-35	35-65	65-85	85-95

Table 1. Risk probability

__Legend__. Probability of occurrence L_i scaled from j = (1,5) is a surrogate for an average subjective probability P_i (Li ↔ Pi) or the range of probabilities presented in Table 1. For example, due to assessment subjectivity, a score of five corresponds to "a very high" probability of 90% or probabilities within the 85% - 95% range.

Impact - S	1	2	3	4	5
Rating	Very low	Low	Medium	High	Very high

Table 2. Risk impact.

__Legend__. Impact Si scaled from j = (1,5) corresponds with qualitative impact assessments from "Very low" to "Very high."

The risk score (1) can be interpreted as a mathematical expectation (average) of the impact S_i. If a risk eventuates, then the impact equals to S_i (2). If not, the impact S_i = 0. Therefore, the risk score M_i can be presented as

$$M_i = S_i \times P_i + 0 \times (1 - P_i) = S_i \times P_i \qquad (2),$$

or based on the conversion presented in Table 1 ($L_i \leftrightarrow P_i$)

$$M_i = S_i \times L_i + 0 \times (L_{max} - L_i) = S_i \times L_i \qquad (3).$$

Therefore, the risk score M_i can be presented as the average impact of a risk.

Traditionally, risk scores are presented in a risk matrix or "heat map" (Figure 1).

Figure 1. Risk score matrix.

The advantages and disadvantages of risk matrices (heat maps) are discussed in [18].

The "heat map" approach could be used to characterize the "riskiness" of the entire clinical trial. The corresponding metric may be presented as a "Total Normalized Risk Score (TNRS)."

$$TNRS = \frac{\sum_i \big(Score\ risk(i)\big)}{\#\ risks} \qquad (4)$$

TNRS defined as the total risk score for high and medium risks selected for the analysis divided by the number of analyzed risks.

If TNRS is in the "red" or "yellow" zone at the risk assessment step, then a mitigation plan for these risks has to be developed. If TNRS is in the "green" zone

after developing a mitigation plan, then the mitigation plan could be satisfactory. Zones' boundaries are arbitrary.

The goal of the modeling technique is to develop a risk mitigation plan where TNRS will be in the "green" zone, depending on a contingency budget.

TNRS has some limitations. For example, although TNRS could be in the "green" zone, some risks could still be in the "red" or "yellow" zone due to limited contingency resources. It means that informal risk analysis should supplement modeling.

Using TNRS could help to rank clinical trials based on their "riskiness" before and after the mitigation.

Risk mitigation

A risk mitigation plan has to answer the critical question in risk planning – what to do if a risk event occurs. There are many options, such as (a) to leave it as is and face unfavorable consequences; (b) to eliminate risk by allocating significant contingency resources, or (c) to find the right balance between the degree of risk mitigation, contingency budget, risk appetite[4], risk capacity[5], and risk tolerance[6], assuming that any mitigation plan is associated with residual risks.

Both under and over-allocation of contingency resources are suboptimal. Under-allocation of the contingency budget could jeopardize clinical trial execution. Over-allocation of a contingency budget, or even incorporating additional resources into a core clinical trial budget to eliminate some risks (assuming that probability is almost 100% which may not be the case), could increase a clinical trial budget.

Mitigation costs. The contingency budget comprises mitigation costs required to mitigate each risk upon its occurrence. They are assigned to each risk mitigation option. The presented technique allows the incorporation of multiple mutually exclusive risk mitigation options associated with a single risk.

---

[4] **Risk appetite** is the amount of risk a clinical trial planner desires to take
[5] **Risk capacity** is the maximum amount of risk that could be taken.
[6] **Risk tolerance** is the amount of risk a clinical trial planner is comfortable taking or the degree of uncertainty the planner can handle.

Deeper risk mitigation corresponds with higher mitigation costs. Additional training, monitoring visits, or backup sites are typical risk mitigation options. Each risk is associated with the probability of occurrence. Therefore, the contingency costs should be multiplied by the probability of occurrence (Table 1) for each risk (5), including reduced risks after the mitigation.

$$\widehat{C}_i = C_i * P_i \tag{5}$$

where $\widehat{C}_i$ - risk-adjusted (average) risk mitigation costs; C_i – mitigation costs, and P_i – the probability of occurrence for i-th risk.

Several empirical approaches are known to address contingency planning in clinical trial budgeting.

a) The first approach is based on the identification of the risks with the highest risk score and the allocation of contingency resources aiming to eliminate these risks.
b) The second approach assumes contingency resource allocation for the pre-selected risks.

Both techniques may not guarantee optimal solutions. Therefore, with increased clinical R&D budgetary constraints and complexities of clinical trials, the need for a method that accurately aligns risk, contingency resources, risk appetite, and risk tolerance cannot be underestimated.

2. Contingency planning methodology for a clinical trial

The effective risk planning process during clinical trial budgeting needs to answer the following questions:

1. How to align the contingency budget with the clinical trial risk landscape?
2. What contingency budget should be allocated to reduce overall clinical trial risk to a certain level, e.g., to reduce TNRS to the green zone (Figure 1))?
3. Should the contingency budget be allocated to eliminate all risks, the highest risks, or to reduce TNRS to a required level by optimizing the contingency budget allocation?
4. How to align risk mitigation, contingency budget, and risk tolerance?

3. The model

The model was developed to optimize the risk mitigation plan. A risk score is calculated for each identified risk from the risk registry using the formula (1). Then risks are sorted according to their risk score. It is assumed that low-score risks are monitored only, not mitigated. For high and medium risks, one or multiple risk mitigation options need to be identified along with resources to reduce them in case of risk eventuation. The corresponding residual risk score[7] is also calculated for each mitigation option.

The model selects an optimal risk mitigation plan minimizing TNRS for the entire portfolio of clinical trial risks or minimizing the contingency budget aiming to "move" TNRS into the "green" zone of the risk matrix (Figure 1). It also allows the optimal allocation of limited contingency resources across different business groups and risk categories.

The model is formulated as a Quadratic Mixed Integer Programming (QMIP) model [19] where some variables are binary (X= 0, 1). QMIP models find the globally optimal value of a function for a certain number of variables, given a set of constraints on these variables (equalities or inequalities).

The model includes four components:

A. Decision variables

$X_i = (0 \text{ or } 1)$. If $X_i = 0$, the i-th risk/risk mitigation option is not selected. If $X_i = 1$, the i-th risk/risk mitigation option is selected. Their value will be defined automatically during model execution.

B. Parameters

All model parameters are estimates.
- For each risk and risk mitigation option - the risk score is calculated using (1)
- Risk-adjusted mitigation cost is calculated using (5) for each risk mitigation option.
- The average contingency budget.

C. Constraints and rules

- The average contingency budget should exceed the total average mitigation costs for selected risk mitigation options

---

[7] If mitigation resources are assigned, it is assumed that the residual risk still exists (e.g., S =1, L=1, M=1).

- Business rules (e.g., forced elimination of risks, forced reduction of highest risks, etc.)
- Others

D. Criteria

Potential criteria may include:

1. Minimum TNRS for selected risks
2. Minimum quadratic TNRS deviation from the TNRS target.
3. Minimum contingency budget
4. Others (e.g., multiple criteria could be used)

The developed technique was applied to the risk planning of a Ph2 clinical trial.

Part 2. Case study

1.   Risks identification and assessment

For a clinical trial, 80 risks[8] across ten risk categories were identified. The risks were separated into two categories – low and medium/high. The number of low risks = 55, number of high/medium risks = 25. Risks allocation across risk categories is presented in Figure 2. Risk categories, risks, and allocation across risk categories are unique for each clinical trial.

Figure 2. Allocation of low and medium/high risks across risk categories.

Low risks may not be as harmful as medium/high risks for clinical trial performance. Therefore, they will be only monitored. Medium/high risks are mitigated in the case study to minimize their impact on clinical trial performance.

Risk mitigation planning. Baseline scenario

The proposed methodology focuses on deriving an optimal risk mitigation strategy for the entire portfolio.

Risk #	Category	Mitigation	Description of Risk/ Description of Mitigation	Probability Score	Severity/ impact score	Risk Score	Mitigation Cost, $	Probability	Probability adjusted costs
1	Recruitment		Recruitment is not completed as planned.						0
		1	10% less subjects are enrolled during the first 3 months of the study. No action	5	4	20	0	0.9	0
		2	22 new sites in two new countries Mitigation	2	1	2	720,000	0.25	180000
2	Clinical Operations		Study cannot be completed on time due to delay in contracting with sites						0
		1	There is one month delay at 25% at sites. No action	4	4	16	0	0.75	0
		2	Add 100 h CRA resources Mitigation	2	1	2	10000	0.25	2500

Table 3. Fragment of the risk registry with risk mitigation options and risk mitigation costs (one mitigation option per risk).

The approach is illustrated in Table 3. It is assumed that each risk has two options: (1) no mitigation and (2) to mitigate risk to minimize its impact and probability. For example, risk #1 is related to a lower-than-expected enrollment rate (10% fewer subjects are enrolled during the first three months of the study). Both impact and probability of occurrence for this risk are high (4 and 5). Overall risk score = 20. The mitigation option for risk #1 is to set up 22 new sites in two new countries. The mitigation cost is 720K. The residual risk score is reduced to 2. The pre-allocation of 22 backup sites will reduce risk#1 impact to 1 and the probability of occurrence to 2. According to Table 2, the probability of risk #1 was reduced from 85%-95% to about 20%-30% (average -25%). Therefore, in contingency planning, probability-adjusted costs for risk #1, according to (5), should be calculated as 720K*0.25=180K.

To develop the most effective risk mitigation plan for identified 25 medium/high risks, 2^{25} = ~33M+ options – to mitigate risk or not – could be potentially considered. It is time-consuming to analyze even a small part of them. If a contingency budget is limited, how to decide which risk to mitigate and which is not?

A. Sorting algorithm.

Many practitioners use the so-called sorting or prioritization algorithm to sort risks according to their risk score. Related cumulative risk-adjusted mitigation costs are added until they exceed the contingency budget. Selected risks are included in a risk mitigation plan, and resources are allocated.

B. An optimal risk mitigation algorithm

The risk mitigation plan based on risk sorting can be improved using the optimization model described above.

Figure 3. Comparison of risk mitigation strategies between sorting and optimization for different contingency budgets

According to Figure 3, the clinical trial TNRS would be about 30% lower if the optimization model had been used compared to the sorting for contingency budgets from ~100K to 500K. Both algorithms generate the same results if the contingency budget is zero or exceeds 700K (large contingency budget - mitigation of all risks).

This result can be improved by incorporating multiple risk mitigation options per risk, as presented in Table 4. In this example, risk #1 (risk of lower enrollment rate) has six mutually exclusive risk mitigation options related to the potential

activation of new sites in different countries (to boost enrollment rate) with corresponding mitigation costs.

Risk No	Category	Mitigation	Description of Risk/ Description of Mitigation	Probability Score	Severity/ impact score	Risk Score	Mitigation Cost, $
1	Recruitment		Recruitment is not completed as planned. The following risk indicators and thresholds were defined:				
		1	10% less subjects are enrolled during the first 3 months of the study. **No action**	5	4	20	0
		2	3 new sites are opened in 5 currently involved countries	4	4	16	40000
		3	4 new sites in two new countries	3	4	12	90000
		4	10 new sites are in 5 currently involved countries	3	3	9	200000
		5	10 new sites in two new countries	2	3	6	250000
		6	22 new sites in 5 currently involved countries	2	2	4	700,000
		7	22 new sites in two new countries	2	1	2	720,000
2	Clinical Operations		Study cannot be completed on time due to delay in contracting with the sites				
		1	There is one month delay at 25% at sites. No action	4	4	16	0
		2	Add CRA resources 100h CRAs	2	1	2	10000

Multiple risk mitigation options

Table 4. Multiple risk mitigation options per risk (risk registry fragment)

Figure 4. Comparison between single and multiple risk mitigation options per risk

As Figure 4 indicates, TNRS is lower if the model with multiple risk mitigation options per risk is used for a contingency budget from 100K to 1M.

The entire optimal risk mitigation plan is presented in Table A (Appendix 1) and its fragment in Table 5 (the selected mitigation option is corresponded with "1", not selected with "0").

The optimization model selected mitigation option #4 for risk #1 (1.4) (Table 6) related to opening ten new sites in two new countries.

risk	Selected mitigation	Description
1	0	10% less subjects are enrolled during the first 3 months of the study. No action
1.1	0	3 new sites are opened in 5 currently involved countries
1.2	0	4 new sites in two new countries
1.3	0	10 new sites are in 5 currently involved countries
1.4	1	10 new sites in two new countries
1.5	0	22 new sites in 5 currently involved countries
1.6	0	22 new sites in two new countries
2	0	Study cannot be completed on time due to delay in contracting with the sites. There is one month delay at
2.1	1	Add CRA resources 100h CRAs

Table 5. Fragment of optimal risk mitigation plan.

b. Contingency resources allocation

The model generates an optimal allocation of contingency budget across risk categories (see Figure 1 for a list of risk categories), as shown in Figure 5.

Figure 5. Contingency budget allocation across risk categories.
Legend. 28% of a contingency budget is allocated for the risk category 10

c. Model analysis. What-if scenarios

1. Forced selection of mitigation option #25.2. Risks interdependence.

#	Risks	Baseline scenario	Mitigation costs, K
23	Batch failure rate is high		0
23.1	Backup – CMO #1		100
23.2	Backup – CMO #2		150
24	Slow drug distribution and resupply process		0
24.1	Faster delivery. Backup carrier		125
24.2	Faster delivery options + Additional depots		175
25	High risk of stock-out		0
25.1	Increase overage by 5%		200
25.2	**Increase overage by 10%**		**225**

Table 6. Fragment of baseline scenario with selected mitigation options

In the baseline scenario, risk #25, related to the high risk of stock-out in clinical supplies, was not mitigated due to a limited contingency budget (Table 6). Risks #23 and #24 were mitigated. The model selected options #23.1 and #24.1 (plus sign). The decision was made to force the mitigation of risk #25 to minimize the risk of stock out. It means allocating 225K to minimize the risk score (forced selection of option #25.2). If option #25.2 for risk #25 is forced to be selected, then risks #23 and #24 cannot be mitigated (Table 7). The proposed risk plan is riskier (TNRS = 3.04 vs. 2.8 in the baseline scenario for the 500K contingency budget).

Risk	Forced risk #25 reduction	baseline
23	1	0
23.1	0	1
23.2	0	0
24	1	0
24.1	0	1
24.2	0	0
25	0	1
25.1	0	0
25.2	1	0
TNRS	3.04	2.8

Table 7. Forced selection of option 2 for risk #25 vs. baseline scenario.

Figure 6. TNRS vs. contingency budget for forced selection of mitigation option #25.2 and the baseline scenario.

Figure 6 illustrates that there is no feasible risk mitigation plan if the contingency budget is less than 300K for this scenario (forced selection of option #25.2).

2. Forced mitigation of high-impact risks

Often high-impact risks are forced to be mitigated. For example, if the impact of a particular risk is five, then the model (with additional rules) can force the selection of mitigation options for each high risk to reduce the impact of each risk with the impact equal to five to four. Modeling experiments indicate that the contingency budget should exceed 200K to meet the impact reduction rule (Figure 7). Otherwise, the model generates an infeasible solution.

Figure 7. TNRS vs. contingency budget for the baseline scenario and forced risk impact reduction scenario

Alignment of contingency budget, risk tolerance, and risk appetite

The optimal contingency planning model described above generates an optimal risk mitigation plan. The model uses "averaged" data, including the optimization criteria, risk mitigation costs, and contingency budget. The model addressed many essential questions, such as optimal risk mitigation strategy selection and contingency budget allocation. However, the model cannot answer how to incorporate risk appetite and tolerance into the contingency budgeting process.

Risk appetite and Risk tolerance are associated with uncertainty due to different stakeholders' expectations. Therefore, it seems natural to define risk tolerance as the probability that a contingency budget will be sufficient to implement a mitigation plan presented in Appendix 1, assuming residual impact and probability for each risk. A lower risk tolerance requires a higher contingency budget and vice versa.

The portfolio of clinical trial-mitigated risks was simulated using binary distribution to analyze risk tolerance (Figure 8).

Figure 8. Monte-Carlo simulation of selected risk mitigation strategy for the portfolio of clinical trial risks. RMO – Risk Mitigation Option

Simulation results

Figure 9. Simulation for a portfolio of risks – empirical probability distribution
Legend: *The horizontal axis is the contingency budget, and the vertical is the risk tolerance level: the lower the risk tolerance, the higher the contingency budget.*

A contingency budget = 500K corresponds to 50% risk tolerance. If a contingency budget equals 500K, there is only a 50% chance that the mitigation strategy will be implemented. If a contingency budget equals 750K, there is an 80% chance that the mitigation strategy will be implemented (20% risk tolerance). Zero risk tolerance (100% that the mitigation strategy will be implemented) requires a ~1.5M contingency budget. Risk capacity is defined as 90% (10% tolerance limit) and fits with a 1M contingency budget.

Smaller companies may have a higher risk tolerance policy than big ones due to resource limitations.

Future research

Future research will focus on the mitigation strategy's effectiveness, alignment of qualitative and quantitative risk assessment, and development of early warning rules (when to start risk mitigation?).

Conclusion
- Effective contingency planning in clinical trial budgeting could substantially reduce risk and save money

- A methodology for optimal risk mitigation planning was developed and validated. It minimizes total normalized risk score (TNRS) under a limited budget and utilizes multiple risk mitigation options per risk
- Modeling experiments demonstrated the effectiveness and efficiency of the model

The author thanks Andor Kanka and Dr. Beata Balati (Balati CRO, Hungary) for sharing data and constructive discussions.

Funding: No funding source was reported.

Conflict of interest: No conflict of interest was reported.

References:

1. Ghone A. Risk Assessment In Clinical Trials – Well Begun Is Half Done. https://www.clinicalleader.com/doc/risk-assessment-in-clinical-trials-well-begun-is-half-done-0001
2. Aven T. Risk assessment and risk management: Review of recent advances on their foundation. European Journal of Operational Research 253 (2016) 1–13
3. Liebig H, Hastings R. Reducing Risk through Mitigation Strategies. Applied Clinical Trials, 2009, August.
4. Bacchieri A, Rossi A, Morelli P. Risk and mitigation actions for clinical trials during COVID-19 pandemic (RiMiCOPa). Contemporary Clinical Trials Communications 20 (2020).
5. Knirsch C, Chappell P, Alvir J, Alemayehu D. Risk Assessment and Mitigation. Applied Clinical Trials, 2012, Volume 21, Issue 4
6. Del Medico A, Trad M, Khinda S, Moody B, Hughes L, Vanbelle C, Tanjga O. Mitigating Risk in Implementing Multi-Regional Trials in MS Applied Clinical Trials-02-01-2018, Volume 27, Issue 2.
7. Bhagat S, Kapatkar V.K, Mourya M, Roy S, Jha S, Reddy R, Kadhe G, Mane A, Sawant S. Potential Risks and Mitigation Strategies Before the Conduct of a Clinical Trial: An Industry Perspective Reviews on Recent Clinical Trials, 2016, 11, 47-55
8. Bowers J, Khorakian A. Integrating risk management in the innovation project. European Journal of Innovation Management 2014 Vol. 17 No. 1, pp. 25-40

9. Mordecai Y. Project risk optimization based on strategy-proof risk assessment. MS Industrial Engineering thesis. Tel-Aviv University. May 2010

10. Guan X, Servranckx T, Vanhoucke M. An analytical model for budget allocation in risk prevention and risk protection. Computers & Industrial Engineering 161 (2021)

11. Micán C, Fernandes G, Araújo M. Project portfolio risk management: a structured literature review with future directions for research International Journal of Information Systems and Project Management, Vol. 8, No. 3, 2020, pp. 67-84.

12. Ben-David, I., & Raz, T. (2001). An integrated approach for risk response development in project planning. Journal of the Operational Research Society, 52(1), 14–25.

13. Chapman C. Project risk analysis and management - PRAM is the generic process. International Journal of Project Management, Volume 15, Issue 5, October 1997, Pp. 273-281.

14. Sato T, Hirao M. Optimum budget allocation method for projects with critical risks. International Journal of Project Management, Volume 31, Issue 1, January 2013, pp. 126-135.

15. Cagno E, Caron F, Mancini M. Dynamic analysis of project risk. Int. J. Risk Assessment and Management, 2008, Vol. 10

16. Thaheem M, De Marco A, Narbaev T. Selecting Appropriate Risk Response Strategies Considering Utility Function and Budget Constraints: A Case Study of a Construction Company. Buildings 2022, 12, 98. Pp.1-19

17. M. Grabowski M, Roberts K. Risk Mitigation in Large-Scale Systems: Lessons from high-reliability organizations. California management review vol 39, no. 4 summer 1997

18. Cox T. What's Wrong with Risk Matrices? Risk Analysis, Vol. 28, No. 2, pp. 497-512.

19. Dorfman, R., Samuelson, P. A., & Solow, R. M. (1986). Linear programming and economic analysis. Revised edition. Mineola, NY: Dover Books on Computer Science.